 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer CMO, effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the companys two commercial-stage products TEGSEDI inotersen and WAYLIVRA volanesorsen and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. ODea, MB, BCh, BAO, FRCPC, will serve as an advisor to the company to ensure a smooth transition. 